Law360, New York (January 11, 2007, 12:00 AM ET) -- As the U.S. House of Representatives prepares to consider a bill changing the Medicare law, the acting director of the Congressional Budget Office has said that requiring the federal government to negotiate Medicare drug prices would not save money as proponents have long contended.
Acting Director Donald B. Marron wrote a letter Wednesday to Rep. John D. Dingell (D-Mich.), chair of the House Committee of Energy and Commerce, saying that negotiation with the drug companies would have a negligible effect because the government would be unable...
Effects Of Proposed Medicare Changes Disputed
To view the full article, take a free trial now.
